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Abstract
Background: Among septic patients admitted to the intensive care unit (ICU), early recognition of those with the
highest risk of death is of paramount importance. Since clinical judgment is sometimes uncertain biomarkers could
provide additional information likely to guide critical illness management. We evaluated the prognostic value
of soluble Triggering Receptor Expressed by Myeloid cells 1 (sTREM-1), procalcitonin (PCT) and leucocyte
surface expression of CD64.
Methods: This was a prospective cohort study, which included 190 septic patient admitted to the ICU in two
hospitals. Blood samples for biomarker measurements were obtained upon admission and thereafter. The
Simplified Acute Physiology Score (SAPS) II and the Sequential Organ Failure Assessment (SOFA) score were
calculated. The primary outcome was all-cause death in the ICU.
Results: The mortality rate reached 25.8 %. The best predictive value of the three biomarkers was obtained
with baseline sTREM-1, although clinical scores outperformed this. Accuracy was greater in patients without
prior exposure to antibiotics and in those with proven bacterial infection. Adding sTREM-1 levels to SAPS II
increased its specificity to 98 %. The soluble TREM-1 level, core temperature and SAPS II value were the only
independent predictors of death after adjustment for potential confounders. A decrease in sTREM-1 with time
was also more pronounced in survivors than in non-survivors.
Conclusions: sTREM-1 was found to be the best prognostic biomarker among those tested. Both baseline
values and variations with time seemed relevant. Although SAPS II outperformed sTREM-1 regarding the
prediction of ICU survival, the biomarker could provide additional information.
Background
Sepsis remains a leading cause of death worldwide,
especially in the intensive care unit (ICU) setting [1].
It is currently accepted that improving the outcome
of critically ill patients with sepsis relies mainly on the ad-
equacy and the timeliness of key interventions such as ad-
ministering appropriate antibiotics and sufficient amounts
of fluid, especially the sickest ones [2].
It is therefore mandatory to accurately assess the se-
verity of the acute illness in such patients. Severity
scores based on the assessment of underlying disease
and organ failure have been derived from large studies
[3]. However, these large cohorts included patients with-
out sepsis. In addition, the interest of repeated clinical
assessments has not been validated with such scoring
systems, and one should consider only the worst values
of the physiological and biological parameters within the
first 24 h following ICU admission. As a result, the
Simplified Acute Physiology Score (SAPS) II is not the-
oretically available before day 2 and finally of limited
value in clinical practice. In contrast, the Sequential
Organ Failure Assessment (SOFA) score, which is easier
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to calculate since it relies solely on daily organ dysfunc-
tion assessment, could be more suitable. In addition, it
was first evaluated in septic patients [4, 5]. However, as
organ failure is the end-stage complication of sepsis, it
would be useful to predict it before it becomes clinically
obvious, in order to prevent or at least to attenuate it
whenever possible. In addition, clinical judgment may
lack objectivity, thus leading to wrong evaluations and
potentially inappropriate interventions. Moreover, the
administration of innovative therapies is thought to pro-
vide the greatest benefit if given early to the potentially
sickest septic patients.
In addition to the clinical evaluation, biomarkers pro-
vide a unique but only theoretical opportunity to pre-
dict the risk of bad outcomes reliably and promptly in
patients with sepsis. Since the host inflammatory re-
sponse is of paramount importance, measuring some of
its most relevant mediators as well as surrogates within
various body fluids including plasma has been proposed
as a promising way to improve the management of such
patients. Among these biomarkers, procalcitonin (PCT)
and the soluble Triggering Receptor Expressed by Myeloid
cells 1 (sTREM-1) have been shown to exhibit good diag-
nostic accuracy for bacterial sepsis [6–8]. More recently,
we showed that the CD64 leucocyte index measured upon
ICU admission was even more accurate [9].
The prognostic value of these biomarkers, however,
remains to be clearly established and compared with
relevant clinical scores. Actually, although it is tempting
to believe that the same biomarker could be both a reli-
able diagnosis tool for sepsis and a powerful outcome
predictor, none of those mentioned above has demon-
strated these abilities within the same cohort of patients.
We therefore assessed the predictive value of PCT,
sTREM-1 and the PMN CD64 index, with regard to the
risk of a bad outcome in a large cohort of ICU septic
patients included in a prospective observational study
that aimed primarily to evaluate their diagnostic accuracy.
Methods
The methodology has already been extensively described
elsewhere [9].
Study population
Briefly, the approval of the institutional review board
and written informed consent were obtained before in-
clusion. All consecutive patients newly hospitalized in
two French medical intensive care units (Nancy and
Dijon) were prospectively enrolled in the study. There
were no exclusion criteria.
Data collection
On admission to the ICU, the following items were re-
corded for each patient: age; sex; severity of underlying
medical condition stratified according to the criteria of
McCabe and Jackson; SAPS II score [10]; Sepsis-related
Organ Failure Assessment (SOFA) score (range, 0 to 24,
with scores for each organ system [respiration, coagula-
tion, liver, cardiovascular system, central nervous system,
and kidney] ranging from 0 [normal] to 4 [most abnor-
mal]) [4]; and the reason for admission to the ICU. The
following baseline variables were also recorded at inclu-
sion: body temperature; leucocyte count; ratio of the
partial pressure of arterial oxygen to the fraction of in-
spired oxygen (Pao2/Fio2); presence of shock, defined as
systolic arterial pressure lower than 90 mmHg with signs
of peripheral hypoperfusion or need for continuous infu-
sion of vasopressor or inotropic agents; and the use of
previous antimicrobial therapy. The length of the ICU
stay and ICU deaths were also recorded.
Two intensivists retrospectively reviewed all of the
medical records pertaining to each patient and inde-
pendently classified the diagnosis as no infection, sepsis,
severe sepsis, or septic shock at the time of admission,
according to established consensus definitions [11]. Only
patients with sepsis, severe sepsis, or septic shock were
kept for the present study.
Measurement of Neutrophil CD64 index, and plasma
levels of Procalcitonin, and sTREM-1
Within 12 h after admission and enrolment in the study,
5 mL of whole heparinized blood was drawn. Sampling
was repeated on days (D) 2,3,5,7,10,14,21, and 28, provided
the patient was still in the ICU. The expression of CD64
on neutrophils and monocytes was measured by quantita-
tive flow cytometry using the Leuko64TM assay (Trillium
Diagnostics, LLC, Brewer, ME). The sample preparation
and flow cytometer setup were based on the manufac-
turer’s instructions. Index calculations were performed
using Leuko64 QuantiCalc software (Trillium Diagnostics,
LLC, Brewer, ME) [12]. Flow cytometry was performed
within 12 h after blood sampling. The whole procedure
took less than 2 h. The reproducibility of measurements
was excellent with a coefficient of variation lower than 5 %.
Procalcitonin concentrations were measured using an
immunoassay with a sandwich technique and a chemilu-
minescent detection system, according to the manufac-
turer’s protocol (LumiTest, Brahms Diagnostica, Berlin,
Germany).
Plasma concentrations of sTREM-1 were measured by
ELISA using the Quantikine kit assay (RnD Systems, MN,
USA) according to the manufacturer’s recommendations.
All analyses were performed in duplicate. Inter and intra-
assay coefficients of variation were lower than 7 %.
Clinical endpoints
The outcome of the included patients was assessed ac-
cording to the two following endpoints: all-cause death in
Charles et al. BMC Infectious Diseases  (2016) 16:559 Page 2 of 12
the ICU and an increasing SOFA score between day 1 and
day 3 as early surrogates for deteriorating organ function.
Given the fact that late mortality may be caused rather by
secondary infections or comorbidities than by sepsis itself,
biomarkers’ predictive value regarding the risk of death
before day-14 was also evaluated.
Statistical analysis
Descriptive results for continuous variables were
expressed as means (±SD) or medians (IQR) depend-
ing on the normality of their distribution as assessed
by the Kolmogorov-Smirnov test. Variables were tested for
their association with the outcome (i.e., death in the
ICU or increasing SOFA scores between D1 and D3)
using the Pearson χ2 test for categorical data and the
Mann-Whitney U test for numerical data. Receiver-
operating-characteristic (ROC) curves were constructed
to illustrate various cut-off values of soluble TREM-1
and PCT. The sensitivity, specificity, positive and nega-
tive likelihood ratios and their confidence intervals
were calculated (19). These values were calculated for
the cut-off that represented the best discrimination as
derived from the Youden index (J = max [sensitivity +
specificity-1]).
To account for wide distributions of data and potential
nonlinear associations with outcomes, if mean baseline
values were found to be significantly different between
survivors and non-survivors, biomarker values were
transformed into quartiles based on their distribution.
The corresponding Kaplan-Meier curves were then con-
structed in order to compare ICU survival between the
different quartiles through a time-dependent analysis,
using the log-rank test.
We also evaluated the value of PCT and sTREM-1 in
predicting the outcome as independent factors using a
Cox model. Any covariate with univariate significance of
p < 0.10 was eligible for inclusion in the model.
Finally, we compared PCT and sTREM-1 with the
clinical scoring systems usually used in critically ill pa-
tients upon ICU admission (i.e., SAPS II and SOFA)
and with serum lactate concentration, regarding their
ability to predict the outcome. Several combinations
were also tested.
Subgroup analyses were conducted in patients with
proven infection (i.e., microbiologically documented) and
in those who were not given antibiotics within the 48 h
preceding ICU admission.
Statview software (Abacus Concepts, Berkeley CA)
and Prism (Graphpad®) were used for the analyses. A
two-tailed p < 0.05 was considered significant.
Results
The whole data set is available as supplementary mater-
ial (Additional file 1).
Baseline characteristics of the study population
Among the 379 patients included in both ICUs during
the study period, 190 were deemed infected (130
[68.4 %] with septic shock), of whom 49 (25.8 %) died in
the ICU (Table 1). As expected, severe sepsis and septic
shock were the main admission diagnoses. Most of
the patients did not have an ultimately or rapidly fatal
underlying disease according to MacCabe classification.
Immunosuppression was reported in 13.7 % of the in-
cluded patients.
Septic episode description
As shown in Table 1, pneumonia was the most frequent
cause of sepsis in our cohort. Most of the patients re-
quired mechanical ventilation as well as vasopressors
upon admission. The mean SOFA score was 9.0 (5.2),
reflecting the severity of organ failure. Cultures proved
sterile in almost 40 % of the patients since antibiotics
had been given prior to ICU admission in 30 % of them.
Otherwise, gram-positive bacteria were more frequently
isolated than gram-negative bacteria. Bacteremia was
detected in around one quarter of the patients.
Outcomes
All cause ICU mortality was 25.8 % in the study popula-
tion. “Early” death (i.e., before day-14) occurred in 45 pa-
tients. The mean length of stay was 9.5 day (5.0 [1–109]).
The mean duration of mechanical ventilation was 6.4 days
(2 [0–90]). In addition, the SOFA score remained stable or
worsened within the first 48 h of sepsis management in 54
(28.4 %) patients.
Predictive value of biomarker baseline values regarding
ICU mortality
In the first set of analyses, the respective predictive value
of each biomarker was assessed by univariate analysis.
While the CD64 index was not associated with the out-
come of the patients, sTREM-1 and PCT elevation was
greater in patients with a bad outcome than in those
without (Table 2). This was especially true and statisti-
cally significant for sTREM-1. After transformation
into quartiles, the 4th quartile of sTREM-1 was signifi-
cantly and markedly associated with a poorer outcome
(Table 2, Fig. 1).
However, the overall predictive values of sTREM-1
and PCT elevation were quite weak according to the
AUROCC calculation (0.64 [0.54–0.74] and 0.62 [0.53–
0.71]; 95 % CI, respectively) (Tables 3, 4 and 5, Fig. 2).
Optimal cut-off values were then determined. Although
the PPV was low, the NPV was found to be greater than
80 % for both biomarkers (Table 3). Interestingly, sTREM-
1 prognostic value was improved if early mortality was
considered, since AUROCC reached 0.75 (0.66–0.84),
while PCT performance remained low (0.62 [0.53–0.72]).
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Lactate elevation performed no better than sTREM-1,
whenever overall or early-mortality was considered.
In contrast, better performances were achieved with
the SAPS II and SOFA scores as compared with bio-
markers. This was especially true for SAPS II (AUROCC
= 0.86 [0.80–0.91]; 95 % CI), with a positive LR reaching
7.34 ([3.30–16.80]; 95 % CI).
Combinations of sTREM-1 and PCT on the one hand,
and sTREM-1 and blood lactate on the other hand were
then evaluated (Table 4). The overall performance of
each biomarker was not improved. Indeed, lactate eleva-
tion in addition to sTREM-1 improved the specificity of
the latter, but decreased the sensitivity, thereby resulting
in an unchanged AUROCC.
The predictive accuracy of sTREM-1 combined with
either SAPS II or SOFA scores was also tested (Table 5).
Interestingly, adding sTREM-1 to the SAPS II score
improved the accuracy of the clinical score, through
increased specificity and an enhanced positive LR. How-
ever, since the sensitivity was reduced, the overall
Table 1 Patient baseline characteristics and septic episode description according to all-cause ICU mortality
Overall (n = 190) Survivors (n = 141) Non survivors (n = 49) p
Age (years) 60.6 (16.6) 58.8 (17.1) 65.7 (13.8) 0.01
SAPS II (points) 52.6 (21.5) 45.7 (17.2) 73.2 (19.9) <0.01
Gender. male (N. [%]) 109 (57.4) 80 (56.7) 29 (59.2) 0.76
McCabe (N. [%]) 0.37
Non fatal 107 (66.9) 97 (68.7) 30 (61.2)
Ultimately fatal (<5 years) 41 (21.6) 31 (22.0) 10 (24.9)
Rapidly fatal (<6 months) 22 (11.6) 13 (9.2) 9 (18.4)
Immunosuppression (N. [%]) 26 (13.7) 18 (12.8) 8 (16.3) 0.53
Main admission diagnosis 0.05
Respiratory distress (N. [%]) 23 (12.1) 21 (14.9) 2 (4.1)
Shock (N. [%]) 107 (56.3) 75 (53.2) 32 (65.3)
Severe sepsis (N. [%]) 21 (14.3) 19 (13.5) 2 (4.1)
Neurologic failure (N. [%]) 22 (11.6) 16 (11.3) 6 (12.2)
Miscellaneous (N. [%]) 17 (8.9) 10 (7.1) 7 (14.3)
Septic episode description
Core temperature (°C) 37.4 (1.2) 37.5 (1.0) 37.1 (1.8) 0.07
Mechanical ventilation (N. [%]) 134 (70.5) 88 (62.4) 46 (93.9) 0.02
Septic shock (N. [%]) 130 (68.4) 85 (60.3) 45 (91.8) 0.02
SOFA (points) 9.0 (5.2) 7.6 (4.6) 13.0 (4.9) <0.01
Infection source 0.03
Lung (N. [%]) 91 (47.9) 68 (48.2) 23 (46.9)
Urinary tract (N. [%]) 27 (14.2) 26 (18.4) 1 (2.0)
Intra-abdominal (N. [%]) 21 (11.0) 15 (10.6) 6 (12.2)
Skin and soft tissue (N. [%]) 11 (5.8) 7 (5.0) 4 (8.2)
Primary bacteremia (N. [%]) 9 (4.7) 4 (2.8) 5 (10.2)
Miscellaneous (N. [%]) 31 (16.3) 21 (14.9) 10 (20.4)
Bacteremia (N. [%]) 47 (24.9) 33 (23.6) 14 (28.6) 0.49
Isolated pathogen 0.13
Gram-positive (N. [%]) 56 (29.6) 44 (31.4) 12 (24.5)
Gram-negative (N. [%]) 43 (22.7) 35 (25.0) 8 (16.3)
Mixed (N. [%]) 6 (3.2) 2 (1.4) 4 (8.2)
Miscellaneous (N. [%]) 9 (4.8) 7 (5.0) 2 (4.1)
None (N. [%]) 75 (39.7) 52 (37.1) 23 (46.9)
Antibiotics started before ICU admission (N. [%]) 57 (30.0) 43 (30.5) 14 (28.6) 0.80
SAPS simplified acute physiologic score, SOFA sequential organ failure assessment, ICU intensive care unit
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accuracy of SAPS II for the prediction of death was
decreased according to the AUROCC.
In addition, the accuracy of the biomarkers was tested
in two clinically relevant subsets of patients, those with
proven infection and those with no antibiotherapy prior
to ICU admission. Interestingly, the performance of
sTREM-1 was enhanced in both groups since the AUR-
OCC reached 0.74 ([0.62–0.86]; 95 % CI) and 0.75
([0.66–0.85]; 95 % CI), respectively (Additional file 2:
Tables S1 and S2). In contrast, the ability of PCT to
predict outcomes was not improved in these groups.
In a second set of analyses, a multivariate model was
built in an attempt to assess the discriminatory power of
sTREM-1 and PCT in predicting outcomes. The relevant
variables likely to influence the outcome according to
the findings of the univariate analysis were then entered
into the model, as described in the methods section.
Strikingly, sTREM-1 was found to be an independent
predictor of death in the ICU (Table 6). Only core
temperature and the SAPS II score also remained strong
predictors of outcomes in our model. Conversely, nei-
ther PCT elevation nor the lactate level at D1 remained
associated with a bad outcome. Similar findings were
Table 2 Biomarkers and other potentially relevant measurements on ICU admission according to all-cause ICU mortality
Survivors (n = 141) Non survivors (n = 49) p
Sepsis biomarkers
PCT (pg/L) 9.1 (32.7) 19.4 (37.4) 0.57
sTREM-1 (ng/L) 671.0 (514.8) 1148.4 (825.3) <0.01
sTREM-1 quartiles <0.01
1st quartile (N. [%]) 40 (28.2) 7 (14.3)
2nd quartile (N. [%]) 39 (27.4) 9 (18.4)
3rd quartile (N. [%]) 40 (28.2) 8 (16.3)
4th quartile (N. [%]) 22 (16.2) 25 (51.0) <0.01
Neutrophils CD64 index 3.1 (2.8) 3.1 (3.1) 0.92
Other
Leukocytes (cells/mm3) 12200 (11100) 14500 (15375) 0.72
Neutrophils (cells/mm3) 10620 (9010) 13940 (13205) 0.47
Platelets (cells/mm3) 152000 (170500) 105000 (145250) 0.05
Lactate (mmol/L) 2.1 (1.9) 4.4 (7.7) <0.01
Lactate quartiles
1st quartile (N. [%]) 40 (29.0) 7 (14.3)
2nd quartile (N. [%]) 39 (28.3) 8 (17.0)
3rd quartile (N. [%]) 38 (27.5) 9 (18.4)
4th quartile (N. [%]) 21 (15.2) 25 (54.3) <0.01
PCT procalcitonin, sTREM-1 soluble triggering receptor expressed on myeloid cells-1
Continuous data are presented as mean (standard deviation) and mediane (interquartile range)





















Survivors 141 91             54              36               24                19              16               15
Non survivors 49 22              9                6                  4                 2       1                 0 
Fig. 1 Survival in the ICU according to the sTREM-1 admission level
quartile. sTREM-1: soluble triggering receptor expressed on myeloid
cells-1; ICU: intensive care unit
Fig. 2 Overall accuracy of various biomarkers and clinical scores
regarding ICU survival of septic patients. PCT: procalcitonin; sTREM-1:
soluble triggering receptor expressed on myeloid cells-1; SAPS:
simplified acute physiologic score; SOFA: sequential organ failure
assessment; ICU: intensive care unit
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obtained when including sTREM-1 quartiles into the
model (Additional file 2: Table S3).
Predictive value of daily variations of biomarkers
regarding ICU death
In addition to one single baseline value, variations of
biomarkers over time could be helpful in predicting the
outcome of patients. We therefore assessed to what ex-
tent daily variations in sTREM-1, PCT and CD64 were
related to death in the ICU. As expected, and in accord-
ance with the above-mentioned findings, sTREM-1 kin-
etics was found to differentiate between survivors and
non-survivors in the ICU (Fig. 3). In contrast, no statisti-
cally significant difference was found regarding this end-
point for either PCT or CD64 variations.
Predictive value of biomarker baseline values regarding
clinical worsening
The ability of blood lactate, sTREM-1 and PCT to pre-
dict the risk of clinical worsening within the first 48 h of
sepsis management as compared with the daily SOFA
score was then evaluated (Table 7). Although the overall
accuracy as assessed through the AUROCC was weak
for all three, the sensitivity and NPV of both sTREM-1
and PCT reached almost 90 %, using threshold values
of 568.8 ng/L and 3.9 μg/L, respectively. A blood lac-
tate level rising above the 3.1 mmol/L threshold was
found to be more sensitive but less specific than the
tested biomarkers, with an NPV and PPV of 75.8 and
50.0 %, respectively. However, the combination of ei-
ther sTREM-1 or PCT with the blood lactate level
did not perform better than either marker alone (data
not shown).
Discussion
Accurately evaluating the severity of acute illness in
septic patients on admission to an ICU is challenging.
It usually relies on a combination of various clinical
and biological data, including the assessment of organ
failure, as well as knowledge of underlying disease(s).
Although of paramount importance, clinical judgment
might be biased given the need for prompt decision-
making. Indeed, having an objective overview of a
patient’s risk of death remains a matter of concern.
Calculating clinical scores is fastidious and could remain
subjective. Measuring biomarkers could overcome these
drawbacks.
The main findings of the present study were the fol-
lowing: (i) the PMN CD64 index had no prognostic
value despite its promising accuracy regarding the diag-
nosis of sepsis; (ii) the predictive value of sTREM-1
regarding the risk of death was greater than that of PCT,
especially when considering early mortality. In addition,
among the biomarkers tested, sTREM-1 was an inde-
pendent predictor of death and sTREM-1 kinetics looked
different between survivors and non survivors. Nonethe-
less, both biomarkers were outperformed by clinical
scores; (iii) the combination of sTREM-1 and SAPS II

















0.64 [0.54–0.74] 54.5 % [40.5–68.0] 78.0 % [70.3–84.5] 49.2 % [40.5–54.6] 81.5 % [70.3–92.4] 2.48 [1.36–4.39] 0.58 [0.37–0.85]
PCT (>11.1 ug/L) 0.62 [0.53–0.71] 66.7 % [52.5–78.9] 55.8 % [47.1–64.2] 37.1 % [28.3–42.5] 81.0 % [67.1–91.4] 1.51 [0.99–2.20] 0.60 [0.33–1.01]
Lactate (>3.2
mmol/L)
0.71 [0.62–0.80] 61.2 % [46.2–74.8] 78.3 % [70.4–84.8] 50.0 % [37.7–61.1] 84.8 % [70.4–92.0] 2.82 [1.56–4.92] 0.49 [0.30–0.76]
SAPS II (>67.5) 0.86 [0.80–0.91] 63.8 % [48.5–77.3] 91.3 % [85.3–95.4] 71.4 % [56.6–90.2] 88.1 % [81.3–90.9] 7.34 [3.30–16.80] 0.40 [0.24–0.60]
SOFA D1 (>7.5) 0.78 [0.71–0.85] 87.5 % [74.7–95.2] 55.1 % [46.4–63.7] 40.8 % [35.5–45.3] 92.6 % [74.7–100] 1.95 [1.39–2.62] 0.23 [0.07–0.54]
AUROCC area under receiver operating characteristics curve, Se sensitivity, Sp specificity, PPV positive predictive value, NPV negative predictive value, LR likelihood
ratio, PCT procalcitonin, sTREM-1 soluble triggering receptor expressed on myeloid cells-1, SAPS simplified acute physiologic score, SOFA sequential organ failure
assessment, ICU intensive care unit
















& PCT (>11.1 ug/L)
0.64 [0.54–0.73] 38.2 % [25.4–52.3] 89.4 % [83.1–93.9] 58.3 % [35.6–73.2] 78.7 % [75.6–85.4] 3.59 [1.50–8.57] 0.69 [0.51–0.90]
sTREM-1 (>954.4 ng/L)
& Lactate (>3.2 mmol/L)
0.62 [0.53–0.72] 29.1 % [17.6–42.9] 95.7 % [91.0–98.4] 49.2 % [29.7–72.5] 83.8 % [79.7–86.2] 6.84 [1.95–26.80] 0.74 [0.58–0.90]
AUROCC area under receiver operating characteristics curve, Se sensitivity, Sp specificity, PPV positive predictive value, NPV negative predictive value, LR likelihood
ratio, PCT procalcitonin, sTREM-1 soluble triggering receptor expressed on myeloid cells-1, ICU intensive care unit
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offered the best accuracy for predicting ICU survival in
our cohort; (iv) none of the indicators tested were valu-
able tools for reliably predicting clinical worsening
within the first 48 h of the ICU stay.
Several studies have aimed to evaluate biomarkers
including sTREM-1 as prognostic factors in critically ill
patients with sepsis. However, despite interesting find-
ings, it remains unclear whether they are of any value or
not (Table 8).
TREM-1 is a member of the immunoglobulin super-
family of receptors that is specifically expressed on the
surface of neutrophils and monocytes. The primary role
of all TREM is both the tuning and integration of mul-
tiple signals rather than the direct initiation of an in-
flammatory response. Soluble TREM-1 is the soluble
form of TREM-1, which is up-regulated when the host
innate immune system is exposed to infectious invaders.
Any sustained increase in the sTREM-1 level indicates
that the overall expression of TREM-1 is continuously
rising, along with the release of larger amounts of pro-
inflammatory mediators. Thereafter, any further increase
in sTREM-1 suggests a protracted inflammatory response
generally related to a poor clinical outcome.
To our knowledge, this study is the largest to date to
evaluate the prognostic interest of measuring sTREM-1
in septic patients. Concerning the predictive value of
baseline sTREM-1 levels, our findings are in accordance
with those obtained by Li et al., who showed in 102 ICU
patients that day-1 sTREM-1 concentrations yielded an
AUROCC of 0.85 regarding the risk of death at day-28
[13]. In this study, PCT was also showed a good predict-
ive value. The far higher mortality rate reported in the
Li et al. cohort than in ours (41.2 vs. 25.8 %, respect-
ively) may account for the greater accuracy in predicting
















& SAPS II (>67.5)
0.68 [0.59–0.78] 38.8 % [25.2–53.8] 98.6 % [95.0–99.8] 91.3 % [58.8–100] 80.3 % [79.3–83.3] 27.30 [5.08–261.50] 0.63 [0.48–0.78]
sTREM-1 (>954.4 ng/L)
& SOFA D1 (>7.5)
0.70 [0.61–0.80] 55.1 % [40.2–69.3] 85.8 % [78.9–91.1] 57.4 % [41.9–72.2] 84.6 % [77.8–89.8] 3.88 [3.20–29.70] 0.57 [0.41–0.76]
AUROCC area under receiver operating characteristics curve, Se sensitivity, Sp specificity, PPV positive predictive value, NPV negative predictive value, LR likelihood
ratio, sTREM-1 soluble triggering receptor expressed on myeloid cells-1, SAPS simplified acute physiologic score, SOFA sequential organ failure assessment,
ICU intensive care unit
Table 6 Independent predictors of all-cause ICU mortality
Hazard ratio 95 % CI p
sTREM-1 1.001 1.000–1.002 <0.01
SAPS II 1.039 1.024–1.053 <0.01
Core temperature 0.773 0.629–0.948 0.01
sTREM-1 soluble triggering receptor expressed on myeloid cells-1, SAPS simplified













































































Fig. 3 Variations with time of sTREM-1, PCT and PMN CD64 index
according to ICU survival of septic patients. PCT: procalcitonin;
sTREM-1: soluble triggering receptor expressed on myeloid cells-1;
ICU: intensive care unit
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death. Moreover, the number of patients with antibiotic
exposure prior to biomarker measurement was quite
high in our study, as was the number of patients with
negative cultures. These characteristics probably dimin-
ished the predictive value of sTREM-1 [14]. Finally,
Jeong et al. also found that the sTREM-1 concentration
on admission was the best biomarker regarding the
short-term prognosis in patients presenting with severe
sepsis, outperforming baseline blood lactate levels [15].
Altogether, however, these results are apparently con-
flicting if compared with the data previously obtained by
our group in 63 septic patients, among whom more than
half presented with shock, that the lower the sTREM-1
baseline level, the poorer the outcome [16]. Similar find-
ings were obtained recently in a small cohort of cancer
patients. Indeed, Ravetti et al. showed that levels of
sTREM-1 over time were higher in survivors than in
non-survivors [17]. This may be subsequent to the dual
significance of plasma levels of sTREM-1. Basically, it
may reflect the overall expression of TREM-1, including
the membrane anchored as well as the soluble form.
Then, high levels might be deleterious for the host since
they could result in an overwhelming inflammatory re-
sponse. Conversely, the release of large amounts of
sTREM-1 could be protective through the neutralization
of yet unknown TREM-1 ligands likely to amplify the
host inflammatory response [18]. An anti-inflammatory
effect of sTREM-1 could then be expected as suggested
by findings made in a small cohort of patients with sep-
sis related to ventilator-associated pneumonia [19, 20].
Moreover, as suggested by previous works, elevated
sTREM-1 does not necessarily reflect TREM-1 gene
expression [21]. In addition, one could speculate that
depending on the immunoassay, either one or more iso-
forms of sTREM-1, with or without its shed form, were
detected, thus accounting for such a discrepancy. Fi-
nally, TREM-1 expression on immune cell surfaces is
known to be highly time-dependent, but also variable
according to the pathogen involved and the source of
infection [14]. Differences may exist regarding these
points in the different cohorts mentioned above and
account for these apparently conflicting findings. How-
ever, the present findings may be more representative
since a larger number of patients were included in two
distinct ICUs.
In addition, we should admit that several other studies
failed to demonstrate any interest of sTREM-1 as a pre-
dictor of prognosis. For example, Phua et al. found that
baseline sTREM-1 was a poor predictor of death in the
ICU, as did Zhang et al. [22, 23]. Procalcitonin per-
formed even better in the former study. One larger study
published by Su et al. showed similar results, although
the sTREM-1 level was probably helpful in diagnosing
sepsis, and in differentiating between sepsis, severe
sepsis and septic shock [24].
To overcome the above-described issues regarding the
interpretation of a single sTREM-1 value, serial measure-
ments are of potential interest. As previously reported, we
showed herein that an early decrease in sTREM-1 levels
was associated with a better outcome in the ICU [15, 16,
23, 25]. The high rate of previous exposure to antibiotics
(around 30 %) in our cohort may account for the lack of
correlation between PCT time-course and the outcome.
Actually, we and others have previously shown in large
cohorts of critically ill patients that a decrease in PCT
levels within the first 72 h of sepsis management was
closely related to the outcome [26, 27].
Finally, we compared biomarkers with clinical scores
since they are still considered the “gold-standard” for
predicting the outcome of critically ill patients [4, 10, 28].
It is worth noting that in our study the AUROCC achieved
with both SOFA on admission and SAPS II was found to
be greater than that for sTREM-1. However, adding
sTREM-1 to SAPS II improved its specificity, since it
reached 98 %, and showed a positive likelihood ratio of
27.3. In addition, the baseline sTREM-1 level remained an
independent predictor of death in the ICU as did the
SAPS II score, after adjustment for potential confounders,
whereas neither lactate levels nor the SOFA score did. We
could then consider that measuring sTREM-1 upon ad-
mission to the ICU, provides relevant information regard-
ing the severity of sepsis in addition to clinical data.
There are, however, some limitations. First, our cohort
was small, thus precluding the external validity of our find-
ings. Second, sTREM-1 levels were not routinely measured
since it relies on one ELISA assay that so far has not been

















0.66 [0.56–0.76] 86.5 % [71.2–95.5] 45.8 % [35.6–56.3] 38.1 % [31.4–42.1] 89.8 % [69.7–100] 1.60 [1.10–2.18] 0.29 [0.08–0.81]
PCT (>3.9 ug/L) 0.61 [0.51–0.71] 88.2 % [72.5–96.7] 36.5 % [26.9–46.9] 33.0 % [27.1–33.1] 89.7 % [66.2–100] 1.39 [0.99–1.82] 0.32 [0.07–1.02]
Lactate (>3.1
mmol/L)
0.60 [0.51–0.68] 43.0 % [32.8–53.7] 76.6 % [66.7–84.7] 50.0 % [40.2–64.7] 75.8 % [60.1–76.3] 1.84 [0.98–3.44] 0.78 [0.56–1.01]
AUROCC area under receiver operating characteristics curve, Se sensitivity, Sp specificity, PPV positive predictive value, NPV negative predictive value, LR likelihood
ratio, PCT procalcitonin, sTREM-1 soluble triggering receptor expressed on myeloid cells-1, SOFA sequential organ failure assessment, ICU intensive care unit
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Nb. of Patients 63 90 52 63 130 (100 with
sepsis)
102 40 with cancer 190
Median Age 61 Unknown Unknown 63.7 58.9 63 67 60.6
Unit ICU ICU ICU ER (and then ICU) ICU ICU ICU ICU
Severity of sepsis Septic shock (53 %) Severe sepsis + Septic
shock (70 %)















Site of Infection Miscellaneous VAP Miscellaneous Miscellaneous Miscellaneous Miscellaneous Miscellaneous Miscellaneous
Overall Mortality 33 % (ICU) 36.7 % 30.7 % (D28) 25.4 % (D28) 43 % (D28) 41.2 % (D28) In cancer patients: 25.8 % (ICU)
34.7 % (ICU)
40 % (D28)
SAPS II 53 (21) Unknown Unknown Unknown Unknown Unknown Unknown 52.6 (21.5)
APACHE 2 Unknown Unknown Unknown Unknown 13.4 (6.1) Unknown In cancer patients
19.9 (5.1)
Unknown
SOFA D0 936 (3.1) Unknown Unknown Unknown 7.8 (4.4) Unknown 6.2 (2.7) 9 (5.2)
Type of sample - sTREM1 - Serum - Serum - Serum - Serum - Serum - Serum - Serum
- sTREM1 - sTREM1 - sTREM1 - sTREM1 - sTREM1 - sTREM1 - sTREM1




Survivors 154 Unknown 193.4 182.4 Unknown 161.95 848 671
Non survivors 94 (p = 0.02) Unknown 240.2 (NS) 514.1 (p =
0.001)
Unknown 320 (p < 0.001) 558 (NS) 1148 (p < 0.01)
sTREM1 cut-off value
(pg/ml)
180 (baseline) 252.05 (baseline) 954.4 (baseline)
Sensitivity 86 % 85.7 % 54.5 %
Specificity 70 % 75.7 % 78 %
AUROCC 0.74 0.856 0.64
PPV 70.6 % 49.2 %




-sTREM1 baseline - sTREM1/IL-6 baseline
ratio
None (sTREM1 increase








D2 for ICU mortality.
AUROCC = 0.69
sTREM1 (baseline
value > 954.4) +
SAPS II (>67.5)














Table 8 Summary of the main clinical studies evaluating sTREM-1 prognostic value (Continued)
- SOFA score baseline
and evolution
- sTREM1 value on D1
for D28 mortality.
AUROCC = 0.75
- IL-6 baseline - SAPS II - SOFA - PCT (baseline
> 10.6 ng/ml)
- Days of MV - SAPS II
- IL-10/IL-6 baseline ratio - sCD163 - SOFA baseline
> 6.5
- Use of corticosteroids - Core Temperature
ICU Intensive Care Unit, ER Emergency Room, PPV Predictive Positive Value, NPV Negative Predictive Value, AUROCC area under receiver operating characteristics curve, sTREM-1 soluble triggering receptor expressed on














automated. Finally, one can argue that given the large pro-
portion of patients with negative bacterial cultures, non-
septic inflammatory states were included in our study.
However, this could be easily explained by the fact that
prior exposure to antibiotics before ICU admission was
quite frequent, thus reflecting “real life” conditions.
Conclusions
In this cohort of critically ill patients with sepsis,
sTREM-1 was found to be the best prognostic biomarker
among those tested including PCT. Although SAPS II
outperformed sTREM-1 regarding the prediction of ICU
survival, the biomarker could provide additional infor-
mation. Accordingly, our findings emphasize the fact
that reliable tools to diagnose sepsis such as PCT are not
necessarily essential to predict the prognosis [29].
Nevertheless, further studies are needed to determine
to what extent measuring sTREM-1 upon ICU admission
in septic patients could be useful for the decision-making
process and for patients selection in the setting of clinical
trials. Moreover, TREM-1 could be considered a potential
therapeutic target in septic patients [30].
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